MARKET

FATE

FATE

Fate Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.69
-0.54
-2.21%
Opening 11:03 05/16 EDT
OPEN
23.98
PREV CLOSE
24.22
HIGH
24.98
LOW
23.36
VOLUME
327.91K
TURNOVER
4.75M
52 WEEK HIGH
97.43
52 WEEK LOW
20.49
MARKET CAP
2.29B
P/E (TTM)
-9.7209
1D
5D
1M
3M
1Y
5Y
While Fate Therapeutics (NASDAQ:FATE) shareholders have made 502% in 5 years, increasing losses might now be front of mind as stock sheds 15% this week
Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders might understandably be very concerned that the share price has...
Simply Wall St. · 05/09 11:32
RGNX, FATE and ALVR are among after hours
Gainers: REGENXBIO  (RGNX) +8%. Passage Bio (PASG) +6%. Yellow Corporation (YELL) +6%. Fluence Energy (FLNC) +6%. Fate Therapeutics (FATE) +4%. Losers: Cytokinetics (CYTK) -5%. Golden Entertainment GDEN -5%. AlloVir (ALVR) -5%. Arcimoto (FUV) -4%.
Seekingalpha · 05/06 21:50
Fate Therapeutics to Present at Upcoming May Investor Conferences
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with canc...
GlobeNewswire · 05/06 20:01
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Zacks · 05/05 14:18
--Wedbush Cuts Price Target on Fate Therapeutics to $42 From $77, Keeps Outperform Rating
MT Newswires · 05/05 08:23
Recap: Fate Therapeutics Q1 Earnings
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/04 21:55
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 21:15
Fate Therapeutics Q1 EPS $(0.68) Beats $(0.76) Estimate, Sales $18.40M Beat $9.40M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.76) by 10.53 percent. This is a 41.67 percent decrease over losses of $(0.48) per share from
Benzinga · 05/04 20:32
More
No Data
Learn about the latest financial forecast of FATE. Analyze the recent business situations of Fate Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
45.00%Buy
15.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FATE stock price target is 86.26 with a high estimate of 135.00 and a low estimate of 42.00.
High135.00
Average86.26
Low42.00
Current 22.64
EPS
Actual
Estimate
-0.66-0.50-0.33-0.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 309
Institutional Holdings: 107.87M
% Owned: 111.63%
Shares Outstanding: 96.63M
TypeInstitutionsShares
Increased
92
5.79M
New
40
5.51M
Decreased
72
5.95M
Sold Out
50
4.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Director
John Wolchko
Non-Executive Vice Chairman/Independent Director
John Mendlein
Chief Financial Officer
Edward Dulac
Senior Vice President
Yu-Waye Chu
Chief Technology Officer
Mark Plavsic
General Counsel/Secretary
Cindy Tahl
Other
Bahram Valamehr
Independent Director
Shefali Agarwal
Independent Director
Timothy Coughlin
Independent Director
Robert Epstein
Independent Director
Robert Hershberg
Independent Director
Karin Jooss
Independent Director
Michael Lee
Independent Director
Xu Yuan
No Data
No Data
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an ideal source for creating cell therapy product candidates. The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.